Rafee W. Talukder, M.D., B.S.
Picture
Positions
- Assistant Professor
-
Medicine
Hematology/Oncology
Baylor College of Medicine
Houston, TX US
Addresses
- McNair Campus (Office)
-
7200 Cambridge St. STE A07.152
Houston, TX 77030
United States
Phone: (832) 957-6500
Fax: (713) 610-4596
- Dan L Duncan Comprehensive Cancer Center (Clinic)
-
The O’Quinn Medical Tower at McNairedical Center
1919 Old Spanish Trail
Houston, TX 77054
United States
Phone: (832) 957-6500
Fax: (713) 610-4596
Education
- BS from Boston College
- 06/2011 - Chestnut Hill, MA
- MD from University of Texas Health Science Center at San Antonio Long School of Medicine
- 06/2016 - San Antonio, TX
- Residency at Baylor College of Medicine
- 06/2019 - Houston
- Internal Medicine
- Fellowship at University of Washington/Fred Hutch Cancer Center
- 07/2023 - Seattle, WA
- Hematology and Medical Oncology
Certifications
- Board Certified in Internal Medicine
- #404075
- American Board of Internal Medicine
Professional Interests
- Bladder cancer
- Prostate cancer
- Kidney cancer
- Testicular cancer
- Melanoma
- Sarcoma
- Phase 1 trials
Professional Statement
Rafee Talukder, M.D is board certified in internal medicine and board eligible in hematology and medical oncology. He is a native Houstonian who went to medical school at the University of Texas Long School of Medicine in San Antonio and completed his internal medicine residency at Baylor College of Medicine. Dr. Talukder then completed his fellowship in medical oncology and hematology at University of Washington/Fred Hutch Cancer Center, where he served as a chief fellow during the second year of his training. His clinical and research focus is on genitourinary oncology (bladder cancer, prostate cancer, kidney cancer, testicular cancer) with an interest in translational research and creating and running clinical trials. World renowned clinical investigators Dr. Petros Grivas and Dr. Evan Yu served as his primary research mentors. Dr. Talukder's goal is to help build and grow the genitourinary oncology program at Baylor College of Medicine and to create and run practice-changing clinical trials. He plans on working with the multi-disciplinary genitourinary oncology group to help provide access to new and innovative clinical trials for our patients in Houston and the surrounding areas.Websites
Selected Publications
- Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, et al "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clin Genitourin Cancer. 2022 Oct; Pubmed PMID: 35778337
- Makrakis D, Talukder R, Diamantopoulos LN, et al "Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer." BJU Int. 2022 Nov; Pubmed PMID: 34597472
- Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, et al "Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma." Clin Genitourin Cancer. 2022 Dec; Pubmed PMID: 36155169
- Chen Y, Talukder R, Merritt BY, et al "Genomic trajectory in leukemogenesis of myeloproliferative neoplasms: a case report." BMC Med Genomics. 2021 May; Pubmed PMID: 34022887
- Bakaloudi DR, Talukder R, Lin GI, Makrakis D, et al "Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience." Clin Genitourin Cancer. 2023 Jun; Pubmed PMID: 37414620
- Talukder R, Makrakis D, Diamantopoulos LN, et al "Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin." Clin Genitourin Cancer. 2022 Apr; Pubmed PMID: 35078711
- Storm EM, Makrakis D, Lin GI, Talukder R, Bakaloudi DR, et al "Role of Underlying Liver Pathology in the Development of Immune-Related Hepatitis: A Case-Control Study." Target Oncol. 2023 Jul; Pubmed PMID: 37358780
- Talukder R, Makrarkis D, Grivas P, Khaki AR "The Evolving Therapeutic Landscape and Role of Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Systematic Review." touchREVIEWS in Oncology & Haematology. 2023 Mar;
- Makrakis D, Bakaloudi DR, Talukder R, Lin GI, et al "Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clin Genitourin Cancer. 2023 Apr; Pubmed PMID: 36481176
Memberships
- American Society of Clinical Oncology
- (07/2020)
- Alpha Omega Alpha Honor Medical Society
- (04/2016)
Log In to edit your profile